References
Nishide T, Hayakawa N, Nakanishi M, Ishii M, Okazaki S, Kimura I, Shibuya E, Mizuki N (2013) Reduction in choroidal thickness of macular area in polypoidal choroidal vasculopathy patients after intravitreal ranibizumab therapy. Graefes Arch Clin Exp Ophthalmol 251:2415–2420
Agawa T, Miura M, Ikuno Y, Makita S, Fabritius T, Iwasaki T, Goto H, Nishida K, Yasuno Y (2011) Choroidal thickness measurement in healthy Japanese subjects by three-dimensional high-penetration optical coherence tomography. Graefes Arch Clin Exp Ophthalmol 249:1485–1492
Yeoh J, RahmanW CF, Hooper C, Patel P, Tufail A, Webster AR, Moore AT, Dacruz L (2010) Choroidal imaging in inherited retinal disease using the technique of enhanced depth imaging optical coherence tomography. Graefes Arch Clin Exp Ophthalmol 248:1719–1728
Alwassia AA, Adhi M, Zhang JY, Regatieri CV, Al-Quthami A, Salem D, Fujimoto JG, Duker JS (2013) Exercise-induced acute changes in systolic blood pressure do not alter choroidal thickness as measured by a portable spectral-domain optical coherence tomography device. Retina 33:160–165
Koizumi H, Yamagishi T, Yamazaki T, Kawasaki R, Kinoshita S (2011) Subfoveal choroidal thickness in typical age-related macular degeneration and polypoidal choroidal vasculopathy. Graefes Arch Clin Exp Ophthalmol 249:1123–1128
Vance SK, Imamura Y, Freund KB (2011) The effects of sildenafil citrate on choroidal thickness as determined by enhanced depth imaging optical coherence tomography. Retina 31:332–335
Dallinger S, Bobr B, Findl O et al (1998) Effects of acetazolamide on choroidal blood flow. Stroke 29:997–1001
Tan CS, Ouyang Y, Ruiz H, Sadda SR (2012) Diurnal variation of choroidal thickness in normal, healthy subjects measured by spectral domain optical coherence tomography. Invest Ophthalmol Vis Sci 53:261–266
Brown JS, Flitcroft DI, Ying GS, Francis EL, Schmid GF, Quinn GE, Stone RA (2009) In vivo human choroidal thickness measurements: evidence for diurnal fluctuations. Invest Ophthalmol Vis Sci 50:5–12
Author information
Authors and Affiliations
Corresponding author
Additional information
This work, or parts of it, has not been published or presented in a conference/seminar. We have no support in financial or other relationships that might lead to a conflict of interest. The manuscript has been read and approved by all the authors; the requirements for authorship as stated earlier in this document have been met, and each author believes the manuscript represents honest work.
Rights and permissions
About this article
Cite this article
Aksoy, Y., Çolakoglu, K. & Kaya, A. Choroidal thickness is affected by many factors which may change the effect of ranibizumab. Graefes Arch Clin Exp Ophthalmol 252, 847–848 (2014). https://doi.org/10.1007/s00417-014-2596-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00417-014-2596-4